https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
However, multivariate analysis revealed that use of denosumab (hazard ratio [HR] 3.67, 95% confidence interval [CI] 1.01-13.31; p = 0.0484), serum calcium 9.2mg/dL (HR 3.16, 95% CI 1.10-9.13; p = 0.033)), and concomitant or prior use of chemotherapeutic agents (HR 4.71, 95% CI 1.51-14.71; p = 0.0076) were independent risk factors for the development of ARONJ. Almost one-quarter of patients had a risk of developing ARONJ within 5years after starting BMA. Low serum calcium, use of chemotherapeutic agents, and use of denosum
Like
Comment
Share
